Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

37.34
+0.53001.44%
Post-market: 37.21-0.1287-0.34%19:53 EDT
Volume:4.30M
Turnover:160.85M
Market Cap:43.50B
PE:62.23
High:37.75
Open:36.79
Low:36.65
Close:36.81
52wk High:37.83
52wk Low:17.82
Shares:1.17B
Float Shares:1.09B
Volume Ratio:0.87
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6000
EPS(LYR):1.21
ROE:9.69%
ROA:5.13%
PB:5.61
PE(LYR):30.86

Loading ...

Teva Pharmaceuticals is Maintained at Overweight by Piper Sandler

Dow Jones
·
Jul 28

Should Teva’s Branded-Drug Pivot and Duvakitug Bet Reshape How TEVA Investors View Earnings Power?

Simply Wall St.
·
Jul 28

Teva Pharmaceutical Industries Limited.. Expected to Post Earnings of 29 Cents a Share - Earnings Preview

Reuters
·
Jul 27

Why Teva Pharmaceutical Stock is a Buy Despite Trump Tariff Threat

Dow Jones
·
Jul 24

Earning Preview: Teva Pharmaceutical Q2 revenue is expected to decrease by 5.44%, and institutional views are mixed-bullish

Earnings Agent
·
Jul 22

What Teva Pharmaceutical Industries (TEVA)'s TEV‑408 Vitiligo Data and Funding Deal Means For Shareholders

Simply Wall St.
·
Jul 17

Colin Cieszynski’s Top Picks for July 15, 2026

Bloomberg
·
Jul 16

US Appeals Court Revives Teva Lawsuit over Lilly Osteoporosis Drug

Reuters
·
Jul 14

Jefferies Keeps Their Buy Rating on Teva Pharmaceutical (TEVA)

TIPRANKS
·
Jul 10

Teva Pharmaceuticals Obtains Rights to Commercialize Polpharma's Biosimilar Candidate to Ocrevus

MT Newswires Live
·
Jul 09

Teva, Polpharma Biologics announce global licensing agreement

TIPRANKS
·
Jul 09

Teva, Samsung Bioepis Partner to Commercialize Eylea Biosimilar Opuviz in Canada

MT Newswires Live
·
Jul 09

Teva, Samsung Bioepis enter commercialization agreement for OPUVIZ

TIPRANKS
·
Jul 09

Movement Alert|Teva Pharmaceutical Industries Falls 5.17% in Regular Trading, Trading at $32.86

Market Focus
·
Jul 08

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD), Teva Pharmaceutical (TEVA) and BridgeBio Pharma (BBIO)

TIPRANKS
·
Jul 08

Teva to advance TEV-‘408 into Phase 2b study in vitiligo in Q4

TIPRANKS
·
Jul 07

Teva - Tev-’408 Shows Improved Skin Pigmentation and no Safety Signals in Phase 1B

THOMSON REUTERS
·
Jul 07

Teva call volume above normal and directionally bullish

TIPRANKS
·
Jul 07

Teva call volume above normal and directionally bullish

TIPRANKS
·
Jul 02

Lowe’s, Kraft Heinz, Teva, Take-Two, HIVE Insider Shock

TIPRANKS
·
Jun 27